Literature DB >> 3128480

X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa.

H J Zweerink1, M C Gammon, C F Hutchison, J J Jackson, G B Pier, J M Puckett, T J Sewell, N H Sigal.   

Abstract

(DBA/N[female] X CBA/2[male])F1 males have been reported to be deficient in producing antibodies against a number of antigens, including carbohydrates (I. Scher, Adv. Immunol. 35:1-71, 1982). We show that F1 male mice, in contrast to females, made less lipopolysaccharide (LPS)-specific antibodies after immunization with heat-inactivated Pseudomonas aeruginosa and had significantly less naturally occurring LPS-specific antibodies. Furthermore, neutropenic males were 50 to 1,000 times more sensitive to challenge with representative isolates belonging to the seven Fisher immunotypes. Administration to neutropenic F1 males of a human monoclonal antibody specific for the O carbohydrates of P. aeruginosa immunotype 2 LPS or administration of serum from rabbits immunized with heat-inactivated P. aeruginosa immunotype 1 raised the level of resistance to bacterial challenge close to that of females. The results show that the X-linked immunodeficient mouse is an excellent model with which to test the protective efficacy of P. aeruginosa-specific monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128480      PMCID: PMC259785          DOI: 10.1128/iai.56.5.1209-1214.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

Review 1.  Bacterial endotoxins and host immune responses.

Authors:  D C Morrison; J L Ryan
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

3.  Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody.

Authors:  J Yother; C Forman; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

4.  Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.

Authors:  L S Young; D Armstrong
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

5.  Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa.

Authors:  G B Pier; H F Sidberry; S Zolyomi; J C Sadoff
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

6.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

7.  Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

8.  Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.

Authors:  S Sawada; T Kawamura; Y Masuho; K Tomibe
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

9.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.609

10.  Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae.

Authors:  D E Briles; C Forman; S Hudak; J L Claflin
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  7 in total

1.  Acquired resistance to Giardia muris in X-linked immunodeficient mice.

Authors:  D L Skea; B J Underdown
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

2.  Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Authors:  Michael P Horn; Adrian W Zuercher; Martin A Imboden; Michael P Rudolf; Hedvika Lazar; Hong Wu; Niels Hoiby; Stefanie C Fas; Alois B Lang
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

3.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors:  H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

4.  Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa.

Authors:  R S Berk; I N Montgomery; L D Hazlett
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

5.  In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

Authors:  G B Pier; D Thomas; G Small; A Siadak; H Zweerink
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

6.  Heterohybridomas that secrete high levels of pseudomonas-specific therapeutic human monoclonal antibodies: their generation and large scale growth in an automated hollow fiber cell culture system.

Authors:  M C Gammon; M H Banas; L E Boccumini; N H Sigal; H J Zweerink
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

7.  Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Authors:  G B Pier; N L Koles; G Meluleni; K Hatano; M Pollack
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.